GSK Boosts Cancer Portfolio, Acquires Nuvalent for $10.6 Billion
Emmanuel Addeh in Abuja GSK has agreed to  buy U.S.-listed cancer drug developer, Nuvalent, for $10.6 billion in its largest deal in more than a decade, marking a major strategic
Original Source
Read the full article at Thisdaylive →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.